GDA

Guanine deaminase · Q9Y2T3 · GDA on Sugi Atlas →

4,286 patent compounds predicted against GDA, 2,807 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Xanthine (SCHEMBL4965)	1.00	3/20
7-Methylxanthine (SCHEMBL235130)	1.00	3/20
Xanthine (SCHEMBL2352524)	1.00	3/20
Xanthine (SCHEMBL447388)	0.96	3/20
Xanthine (SCHEMBL1507586)	0.96	3/20
Xanthine (SCHEMBL2454001)	0.96	3/20
Xanthine (SCHEMBL389887)	0.82	3/20
Uric Acid (SCHEMBL439505)	0.82	3/20
Xanthine (SCHEMBL3514682)	0.82	3/20
7-Methylxanthine (SCHEMBL2466924)	0.77	3/20
Uric Acid (SCHEMBL3669633)	0.70	3/20
Xanthine (SCHEMBL1495091)	0.66	3/20
Caffeine (SCHEMBL2355447)	0.59	3/20
Theobromine (SCHEMBL4018409)	0.56	3/20
SCHEMBL10998	0.53	3/20
SCHEMBL4560085	0.53	3/20
SCHEMBL10997	0.44	3/20
SCHEMBL740931	0.44	3/20
SCHEMBL932609	0.44	3/20
Uric Acid (SCHEMBL2786719)	0.44	3/20

Clinical trials — most relevant to GDA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3	PHASE2/PHASE3	WITHDRAWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Gene Therapy ADA Deficiency	PHASE1/PHASE2	COMPLETED
High-Dose Ambroxol in GBA1-Related Parkinson	PHASE1/PHASE2	UNKNOWN
Antifolate Effectiveness in Arthritis	PHASE2	COMPLETED
Ambroxol as a Treatment for Parkinson's Disease Dementia	PHASE2	UNKNOWN
Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery	PHASE2	COMPLETED
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	PHASE2	ACTIVE_NOT_RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector	PHASE1	COMPLETED
An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease	EARLY_PHASE1	RECRUITING
Biomarker Analysis for GBA Associated Parkinson's Disease	nan	UNKNOWN
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease	nan	COMPLETED
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease	nan	UNKNOWN
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)	nan	UNKNOWN
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers	nan	COMPLETED
A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition	nan	COMPLETED
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories	nan	UNKNOWN
Polymorphisms, Caffeine and Sleep Disorders	nan	COMPLETED
Assessment of Neurological Manifestations in Gaucher Disease Patients	nan	UNKNOWN
Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease	nan	ENROLLING_BY_INVITATION
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth	nan	COMPLETED
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease	nan	RECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
High Order Spectral Analysis of Local Field Potential Data on a Subgroup of Parkinson's Disease Patients Who Are Carriers of Mutations in the Glucocerebrosidase (GBA) Gene Undergoing DBS Electrode Placement	nan	COMPLETED
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GDA binder may also engage these)

Protein	Name	Similarity
Q5RAV9	—	1.000	Q5RAV9 →
Q9R111	—	0.999	Q9R111 →
Q9WTT6	—	0.999	Q9WTT6 →
Q07729	—	0.997	Q07729 →
O14057	—	0.993	O14057 →
Q86AW9	—	0.992	Q86AW9 →
P34480	—	0.990	P34480 →
Q9VMY9	—	0.987	Q9VMY9 →
A0A1U9YI27	—	0.986	A0A1U9YI27 →
Q6CM42	—	0.985	Q6CM42 →
Q6Q886	—	0.985	Q6Q886 →
O59832	—	0.982	O59832 →
P53095	—	0.981	P53095 →
Q9FMP3	—	0.980	Q9FMP3 →
Q9VR81	—	0.980	Q9VR81 →
P32375	—	0.980	P32375 →
Q55CY3	—	0.980	Q55CY3 →
A8X354	—	0.980	A8X354 →
Q95Q18	—	0.979	Q95Q18 →
Q9VHF2	—	0.978	Q9VHF2 →
P53909	—	0.978	P53909 →
Q561L6	—	0.978	Q561L6 →
B4PUM2	—	0.978	B4PUM2 →
B5VKE8	—	0.978	B5VKE8 →
Q9UTI0	—	0.978	Q9UTI0 →
Q12676	—	0.978	Q12676 →
P32748	—	0.978	P32748 →
Q9P6I7	—	0.978	Q9P6I7 →
P00931	—	0.978	P00931 →
O94544	—	0.977	O94544 →